FDA Approves Vera's Trutakna for IgA Nephropathy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Vera Therapeutics' drug Trutakna, a dual-target therapy for the kidney disease IgA nephropathy, according to coverage from STAT, Reuters, and Fierce Pharma.
- Vera now faces a three-way IgAN market battle with Novartis and Otsuka, and the company's stock jumped on the approval news, per Fierce Pharma and the Wall Street Journal.
Why it matters: Vera now competes in the IgAN market against Novartis and Otsuka, two established players that already operate in the kidney-disease space. With FDA approval secured, the company faces its next test: converting regulatory clearance into commercial market share, while investors rewarded the news with a stock jump.
